Anavex Life Sciences (NasdaqGS:AVXL) Q1 2026 Earnings call February 09, 2026 08:30 AM ET Speaker1 Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2026 First Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. At this time, all participants are in a listen- only mode. Later we will conduct a question-and-answer session, and during this session if you would like to ask a question please use the Q&A box or raise your hand. Please note this confe ...

Key Takeaways Moderna is expected to beat Q4 estimates, with sales projected at $661.4M and a loss of $2.60 per share.COVID-19 vaccines are expected to drive most sales, while the RSV vaccine mResvia faces tough competition.Investors await updates on intismeran studies and FDA resubmission plans for the COVID-flu combo vaccine.We expect Moderna (MRNA) to surpass expectations when it reports fourth-quarter and full-year 2025 results on Feb. 13, before the opening bell. The company’s earnings beat estimates b ...

TEL AVIV, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that its Board of Directors has appointed Geno J. Germano as Chairman of the Board, effective February 4, 2026. Mr. Germano succeeds Gerald Lieberman, who is stepping down as Chairman. The appointment follows a period of accelerating progress across Entera’s pipeline as the Company plans to advance two oral PTH ...

Core Insights - Eli Lilly has agreed to acquire Orna Therapeutics, a genetic-medicine biotechnology company, for a total consideration of up to $2.4 billion in cash [1] Company Summary - The acquisition reflects Eli Lilly's strategic focus on expanding its capabilities in genetic medicine [1] - Orna Therapeutics specializes in innovative genetic therapies, which aligns with Eli Lilly's growth objectives in the biotechnology sector [1] Financial Implications - The deal is valued at up to $2.4 billion, indicating a significant investment by Eli Lilly in the biotechnology space [1]

Core Insights - Caris Life Sciences will report its fourth quarter and full year 2025 financial results on February 26, 2026, and will host a conference call to discuss these results [1] Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, focused on developing and commercializing innovative healthcare solutions [2] - The company utilizes comprehensive molecular profiling, including Whole Genome, Whole Exome, and Whole Transcriptome Sequencing, combined with advanced AI and machine learning to analyze the molecular complexity of diseases [2] - Caris has established a large-scale, multimodal clinico-genomic database and computing capability, which supports the development of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection, and drug development [2] Company Background - Founded with the vision to harness the potential of precision medicine to enhance human health, Caris Life Sciences is headquartered in Irving, Texas, with additional offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland [3] - The company or its distributor partners provide services in the U.S. and various international markets [3]

Core Insights - Oragenics, Inc. is advancing ONP-002, a novel intranasal neurosteroid, as a potential first pharmacological treatment for concussion and mild traumatic brain injury (mTBI) [1][3][11] - The company is well-prepared to initiate clinical site onboarding and first patient dosing in Australia for a Phase 2 clinical trial [1][2][8] Clinical Development - The Phase 2a clinical trial will evaluate 40 patients who meet specific enrollment criteria, with dosing occurring within 12 hours of concussion [10] - The trial aims to assess safety and tolerability through follow-up visits, including nasal examinations and neurocognitive testing [10] - Interim data from the Phase 2a trial is expected throughout 2026, with a final readout anticipated in Q4 2026 [8] Market Opportunity - The global concussion market is projected to exceed $9 billion by 2030, with ONP-002 positioned to be the first commercial treatment in this space [3][5] - The nasal drug delivery market is expected to reach nearly $93 billion by 2030, indicating significant potential for ONP-002 if approved [5] Financial Position - Oragenics raised $16.5 million through a public offering of Series H convertible preferred stock and warrants, supporting ongoing clinical development [8] - The company maintains a clean balance sheet with zero debt, fully funding the Phase 2a trial [8] Strategic Collaborations - A strategic collaboration has been formed with Receptor.AI to enhance drug discovery capabilities, potentially expanding the company's molecule portfolio beyond ONP-002 [8]

Vancouver, Canada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-ba ...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company’s next Annual General Meeting (AGM) as their terms conclude. The planned changes to ProQR’s Board compositio ...

Anixa Biosciences, Inc. (NASDAQ:ANIX) on Monday provided an update on patient outcomes observed in its ongoing Phase 1 ovarian cancer CAR-T clinical trial, following regulatory approval of a protocol amendment that enables substantial dose escalation.Trial OverviewLiraltagene autoleucel, or lira-cel, targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells, but not in healthy tissue.The ongoing Phase 1 trial is enr ...

TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced that a scientific team led by Dr. Justin Chun at the University of Calgary has published new data in the peer-reviewed journal Inflammation Research identifying interleukin-32 (IL-32) as a novel lipid droplet-associated cytokine that may contribute to tubular injury and inflammation in diabetic kidney disease (DKD). The newly published findings, based on human kidne ...